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Lipid mediators of insulin resistance : ceramide signalling down-regulates
GLUT4 gene transcription in 3T3-L1 adipocytes
Sheree D. LONG and Phillip H. PEKALA*
Department of Biochemistry, School of Medicine, East Carolina University, Greenville, NC 27858, U.S.A.
We have previously demonstrated that chronic exposure of 3T3-
L1 adipocytes to tumour necrosis factor-α (TNF) resulted in a
marked decrease (￿ 90%) in cellular GLUT4 (insulin-responsive
glucose transporter) mRNA content as a result of a decreased
transcription rate of the GLUT4 gene (￿ 75%) and a reduced
half-life of its mRNA (9 to 4.5 h). Investigation of the signalling
mechanism responsible for this regulation demonstrated that in
the 3T3-L1 adipocytes, sphingomyelin levels decreased to 50%
of control levels within 40 min of exposure to TNF, consistent
with activation of a sphingomyelinase. In the same manner as
with TNF, treatment of the adipocytes with 1–3 µMC
￿
-ceramide,
amembrane-permeable analogue of ceramide, decreasedGLUT4
mRNA content by ￿ 60%. Subsequent investigations revealed
INTRODUCTION
The adipocyte is no longer viewed as a passive participant in the
processes of energy storage and release, but rather as the centre
of a key regulatory system for maintenance of energy homoeo-
stasis and body composition [1]. Previously, the adipocyte has
been suggested to function as an endocrine cell capable of
producing and secreting molecules with regulatory potential,
including the product of the ob gene and the cytokine, tumour
necrosis factor-α (TNF) [2–5]. The increased expression of TNF
in the adipocytes of obese animals and humans is consistent with
a role for TNF as a mediator of insulin resistance in the obese
state [2,6].
Studies have suggested a role for a number of cytokines,
especially TNF, as potential mediators of glucose homoeostasis
in various tissues [7]. Evidence from both whole-animal and cell-
culture studies has demonstrated that TNF inhibits insulin-
stimulated glucose uptake in adipose tissue and skeletal muscle
[8–11]. The molecular mechanisms by which TNF induces insulin
resistance in cell culture or in whole animals is not clear.
Considerable attention is now being focused on the intrinsic
catalytic activity of the insulin receptor and downstream sig-
nalling events. In murine 3T3-L1 or 3T3-F442A adipocytes,
TNF treatment has been reported to result in a decrease in both
the insulin-stimulated autophosphorylation of the insulin re-
ceptor and phosphorylation of insulin receptor substrate 1 [3,12].
This decrease in the intrinsic tyrosine kinase activity of the
receptor was suggested to be an important component of the
TNF-induced insulin resistance in obese models ; however, it is
not the only mechanism whereby TNF may mediate insulin
resistance. A second model involves the TNF-induced sup-
pression of the gene encoding the insulin-responsive glucose
transporter, GLUT4. Previous work has shown that TNF-
Abbreviations used: TNF, tumour necrosis factor-α ; GLUT4, insulin-responsive glucose transporter ; GLUT1, basal, growth-related glucose
transporter ; SM, sphingomyelin ; SMase, sphingomyelinase ; AA, arachidonic acid ; ETYA, eicosatetraynoic acid, the acetylenic analogue of arachidonic
acid ; cPLA2, cytosolic phospholipase A2 ; PKCζ, the ζ-isoform of protein kinase C; DMEM, Dulbecco’s modified Eagle’s medium; FBS, fetal bovine
serum; DTT, dithiothreitol ; EMSA, electrophoretic mobility shift assay ; MAP, mitogen-activated protein.
* To whom correspondence should be addressed.
that transcription of the GLUT4 gene was reduced by￿ 65% in
response to C
￿
-ceramide, demonstrating that the decrease in
mRNA content is mediated by a reduction in the transcription of
the gene. No eﬀect on GLUT4 mRNA stability was observed
after exposure of the adipocytes to C
￿
-ceramide. These obser-
vations are interesting in light of our previous data demonstrating
that TNF aﬀects bothGLUT4 transcription andmRNA stability
in the 3T3-L1 adipocytes. In conclusion, the eﬀect of ceramide
on GLUT4 gene expression is at the level of transcription,
suggesting that another pathway controls mRNA stability. These
data establish that ceramide-initiated signal transduction path-
ways exist within the adipocyte, and provide a potential mech-
anism for control of GLUT4 gene expression.
treatment results in the down-regulation of GLUT4 mRNA and
protein in cultured adipocytes and muscle cells [2,9,10,13].
Furthermore, GLUT4 protein is also known to be deficient in
adipose tissues of certain obese animal models, as well as humans
with non-insulin-dependent diabetes mellitus [14,15], suggesting
that TNF-mediated insulin resistance may involve the regulation
of GLUT4 gene expression. It remains to be determined whether
the eﬀects of TNF are due primarily to the modulation of
GLUT4 gene expression or to broader eﬀects on the insulin
signalling pathway. Regardless of which model may explain the
TNF-induced insulin resistance, it is important to define the
signal transduction pathways through which the cytokine exerts
its eﬀects.
The sphingomyelin (SM) cycle has been demonstrated to play
a major role in signal transduction pathways initiated by TNF
[16–18]. Initiation of the cycle has been suggested to occur
through activation of a C-type phospholipase associated with the
plasma membrane known as the neutral sphingomyelinase
(SMase) [19]. In response to ligand occupation of its receptor, the
SMase is activated and catalyses the hydrolysis of membrane
SM, generating phosphocholine and ceramide. Ceramide then
serves as a second messenger, activating specific phosphatases
and kinases. The ceramide-activated protein phosphatase
(CAPP), a group-2A protein phosphatase that is inhibited by
okadaic acid, is a potential target [20,21]. This enzyme trans-
locates to the plasma membrane on activation by ceramide and
is involved in the induction of c-myc. A second target has been
shown to be the ceramide-activated, protein-directed, membrane-
bound serine￿threonine protein kinase. This kinase may also
involve communication through Raf, MEK [mitogen-activated
protein (MAP) kinase kinase] and MAP kinases prior to ac-
tivation of gene transcription [17,22,23]. Through these pathways,
ceramide has been shown to play a role in activation of the
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transcription factor NF-κB [17,24,25], and prostaglandin release,






Studies by Hannun and colleagues have suggested that arachi-
donic acid (AA) mediates the TNF-stimulated SM hydrolysis





Examination of the kinetics of SMase activation has provided
evidence that the TNF-induced activation of cPLA
￿
, and release
of AA from the sn-2 position of phosphatidylcholine, precede
TNF-stimulated SM hydrolysis. Thus, after TNF binds to its
receptor, the proposed pathway includes an initial activation of
cPLA
￿
generating free AA, which in turn could activate the
SMase. Jayadev et al. [26] further demonstrated that other fatty
acids (18:1, 18:2, 18:3, 16:0 and 14:0) and the non-
metabolizable analogue of AA, eicosatetraynoic acid (ETYA)
can induce SM turnover with potencies similar to AA, suggesting
that free AA and not a metabolite was responsible for SMase
activation.
Our laboratory has been studying the mechanism by which
TNF can alter expression of the insulin-responsive glucose
transporter (GLUT4). Previously we have demonstrated that
exposure of fully diﬀerentiated 3T3-L1 adipocytes to either TNF
or AA results in attenuation of GLUT4 gene transcription (50%




creased from 9 h to 4.5 h) [13,27]. These observations suggested
that both AA and TNF may alter GLUT4 gene expression by
similar mechanisms. We recently demonstrated that AA may act
via two independent mechanisms to suppress the GLUT4 gene in
3T3-L1 adipocytes [28] ; one of these involves the oxidation of
AA to prostaglandin E
￿
, which functioned in an autocrine
fashion to increase cAMP levels. We [13], as well as Kaestner et
al. [29], have demonstrated that cAMP analogues are capable of
down-regulation of GLUT4 gene transcription. The second
pathway, non-oxidative in nature, can be activated by ETYA, a
non-metabolizable analogue of AA, as well as other fatty acids
that cannot be converted into E-series prostaglandins. These
observations were similar to those of Jayadev et al. [26] described
above and led us to suggest that fatty acids may function to
suppress GLUT4 gene expression through activation of the
neutral SMase. However, in this study we demonstrate that TNF
activates SMase independently of AA and, while ceramide is
demonstrated to be a principal mediator of TNF-induced down-
regulation of GLUT4 gene expression, it does not appear to be
generated by the neutral SMase described by Jayadev et al. [26].
EXPERIMENTAL
Materials
Recombinant human TNF was generously provided by Biogen
(Cambridge, MA, U.S.A.). The specific activity was 9.6￿10￿
units￿mg of protein, based on a cytotoxicity assay using L929
cells. The endotoxin contamination was 0.12 ng￿mg of protein,
basedon aLimulus amoebocyte lysate assay (Sigma).C
￿
-ceramide
was obtained from Biomol. Dulbecco’s modified Eagle’s medium
(DMEM) was purchased from Life Technologies, Inc. Fetal
bovine serum (FBS) was purchased from HyClone (Logan, UT,
U.S.A.) and used at a 1:10 dilution in DMEM. Based on
specifications provided by HyClone, the mean AA content of
culture medium containing 10% (v￿v) FBS would be ￿ 3 µM.
Radiolabelled compounds were obtained from DuPont NEN.
Hybond-N blotting membrane was purchased from Amersham
Co. Deoxyribonucleotides were obtained from Pharmacia LKB
Biotechnology, Inc. Klenow fragment and TRIzol Reagent were
obtained from Gibco BRL Life Technologies. All fatty acids
were purchased fromCayman Chemical, Ann Arbor, MI, U.S.A.
The polyclonal antisera against protein kinase Cζ (PKCζ), as
well as the immunizing peptide, were purchased from Boehringer
Mannheim GmbH, Germany. All other chemicals, unless other-
wise stated, were of molecular biology grade and purchased from
Sigma.
3T3-L1 cell culture
The murine 3T3-L1 cells used in this study were originally
obtained fromDr. Howard Greene, Harvard University, Boston,
MA, U.S.A. Cells were cultured, maintained, and diﬀerentiated
as previously described [27]. The cells were maintained for 10
days post-diﬀerentiation and then treated with the indicated
agents for various times prior to RNA isolation. Concentrations
of TNF used in the study were based on previous studies
[9,10,13]. The concentrations of C
￿
-ceramide added were de-
termined by preliminary experiments over a concentration range
from 0.1 µM to 10 µM (based on an estimated intracellular
concentration of 0.1 µM to 0.5 µM after TNF treatment).
Concentrations at the upper end of this range were lethal to the
cells.
SM assay
Cells were labelled with [￿H]choline chloride (specific radio-
activity of 1 mCi￿ml) at 0.5 µCi￿ml for 6 days after initiation of
diﬀerentiation and then the cells were grown in normal media for
the remaining 3 days. On day 9 the cells were treated with 5 nM
TNF and the lipids were extracted and labelled. SM was
quantified by the bacterial SMasemethod as described by Jayadev
et al. [26].
RNA isolation and Northern blot analyses
Total RNA was isolated by extraction with guanidine isothio-
cyanate and centrifugation through 5.7 M caesium chloride [30]
or by the TRIzol method (Gibco BRL Life Technologies).
Northern blot analyses were performed as described previously
[9].
Nuclei isolation and transcription run-on assays
Nuclei isolated from appropriately treated 3T3-L1 adipocytes
were used in run-on transcription assays as previously described
[31].
DNA probes
The following DNA probes were used: GLUT1, a 2.7 kb EcoR1
fragment encoding the murine 3T3-L1 homologue of the
HepG2￿brain glucose transporter [32] ; GLUT4, a 2.8 kb EcoR1
fragment encoding the 3T3-L1 homologue of the adipose￿muscle
(insulin-responsive) glucose transporter [32] ; and β-actin, a 1.9 kb
HindIII fragment obtained from Dr. D. W. Cleveland [33].
Genomic 3T3-L1 DNA was isolated as described by Gross-
Bellard et al. [34] and digested with EcoRI prior to use in run-on
assays.
Preparation of nuclear extract
After the indicated treatments for various times, the cells were
pelleted in PBS for 10 min at 1000 g. The pellet was then
resuspended in 3 ml of M3 lysis buﬀer (250 mM sucrose, 25 mM
Tris, pH 7.8, 1.1 mM MgCl
￿
, 0.2% Triton X-100, 0.5 mM
PMSF, 10 mM EDTA, 10 mg￿ml leupeptin and 1 mg￿ml
aprotinin) and centrifuged at 12000g for 15 min. The nuclei were
extracted using 250 µl of cold M4 extraction buﬀer [20 mM
Hepes, pH 7.8, 0.4 M KCl, 2 mM dithiothreitol (DTT), 20%
(v￿v) glycerol, 0.5 mM PMSF, 10 mM EDTA, 10 mg￿ml leu-
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peptin and 1 mg￿ml aprotinin) for 30 min and then the nuclear
debris and DNA were pelleted at 17500 g for 15 min. Nuclear
extracts were assayed for protein concentrations by the method
of Bradford [35].
Autophosphorylation of PKCζ
Day 10 adipocytes (60-mm-diam. dishes, 1￿10￿ cells) were
incubated in phosphate-free medium for 2 h. Then 50 µCi￿ml
[￿￿P]P
i
was added for an additional 4 h after which time the cells
were exposed to TNF (5 nM) or C
￿
-ceramide (3 µM) for the
appropriate times. The cells were washed once in ice-cold PBS
and lysed in 50 mM Tris￿HCl, pH 7.4, 150 mM NaCl, 2 mM
PMSF, 100 µg￿ml leupeptin, 0.5% Triton X-100, 5 mM EDTA,
20 mM p-nitrophenyl phosphate, 1 mM NaF and 1 mM sodium
orthovanadate. Immunoprecipitation was achieved using a poly-
clonal antiserum against PKCζ (Boehringer Mannheim GmbH,
Germany) as per Boehringer’s instructions. PKCζ was separated
by SDS￿PAGE and autophosphorylation analysed on auto-
radiograms of KodakX-OMAT films. Specificity of the immuno-
precipitation was demonstrated by competition studies using the
antigen peptide provided by Boehringer Mannheim, which
consists of amino acids 577–592.
Electrophoretic mobility shift assay (EMSA)
EMSAs were performed using the classic NF-κB response
element corresponding to the NF-κB site in the HIV-LTR [36]
(5￿-AATTTCCCTGGAAAGTCCCCAGCGGAAAGTCCCT-
TGT-3￿). Briefly, ￿ 100 ng (60000 c.p.m.) of a ￿￿P-labelled
double-stranded DNA oligomer was incubated with 5 µg of
nuclear extract for 15 min at room temperature in a total volume
of 20 µl of reaction buﬀer [25 mM Tris, pH 7.8, 0.5 mM EDTA,
88 mM KCl, 1 mM DTT, 150 µg of poly(dI.dC)-poly(dI.dC),
0.05% Triton X-100 and 12.5 µg￿ml salmon sperm DNA].
Reaction mixtures were subjected to electrophoresis on 5% non-
denaturing polyacrylamide gels at 4 ￿C, at 40 A (200 V), for
￿ 2 h. The gels were dried and exposed to X-ray film for 12 h
at ￿80 ￿C.
RESULTS
TNF induces SM turnover in 3T3-L1 adipocytes
TNF has been demonstrated to induce SM hydrolysis in HL-60
cells [37] and NIH-3T3 fibroblasts [38] in a time- and dose-
dependent manner with the generation of phosphocholine and
ceramide. The eﬀects of TNF on activation of SMase in 3T3-L1
adipocytes were determined by measuring SM hydrolysis. Treat-
ment of the adipocytes with 5 nM TNF resulted in maximal SM
turnover of approx. 55% of basal, which was observed as early
as 40 min after TNF addition (Figure 1A). Coincident with these
results, previous studies from our laboratory have demonstrated
that free ceramide levels rise to ￿ 74% above basal within
45 min of TNF treatment (P. H. Pekala and Y. A. Hannun,
unpublished work), consistent with TNF activation of a SMase.
The eﬀects of exogenous AA on SM turnover in the adipocytes
were also determined since AA is a potential mediator of TNF
and has also been shown to activate SMase in HL-60 cells [26].
However, in contrast to TNF, AA does not significantly induce
SM hydrolysis, as seen in Figure 1(A). AA treatment resulted in
a slight decrease in SM levels (approx. 10–15%) after 2 h,
suggesting that AA does not activate SMase in the 3T3-L1
adipocytes. In addition, two other fatty acids, oleic acid (18:1)
and ETYA, were tested for their ability to activate SMase
(Figure 1B). The results demonstrated that, like AA, neither oleic
acid nor ETYA induced SM turnover in the cells.
Figure 1 Time course of TNF-stimulated SM hydrolysis
(A) [3H]Choline-labelled adipocytes were treated at time 0 with 5 nM TNF or 100 µM AA. At
the indicated times cells were harvested, lipids were extracted, and SM was quantified as
described in the Experimental section. The data are plotted as the mean percentages of SM
remaining￿S.D. and are representative of results from three separate experiments. (B) As
described in (A) with the exception that the cells were treated at time 0 with 5 nM TNF or
100 µM oleic acid (18 : 1) or 100 µM ETYA. As indicated above the data are plotted as the
mean percentages of SM remaining￿S.D. and are representative of results from three separate
experiments.
C6-ceramide suppresses GLUT4 mRNA levels
TNF activation of SMase and generation of ceramide has been
suggested as an eﬀectormechanismmediating biological activities
of TNF [16]. Ceramide has been implicated as a mediator of the
eﬀects of TNF such as programmed cell death [39] and monocyte
diﬀerentiation inHL-60 cells [22]. To establish a role for ceramide
in the TNF-induced GLUT4 mRNA suppression, fully dif-
ferentiated 3T3-L1 adipocytes were treated with the membrane-
permeable C
￿
-ceramide for 12 h at 1 and 3 µM as shown in
Figure 2. The levels of GLUT4 mRNA were determined via
Northern blot analysis using cDNA probes corresponding to
either GLUT4 or β-actin (results not shown), and quantification
of the hybridization pattern of each mRNA species was de-
termined by phosphorimager analysis. As a result of C
￿
-ceramide
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Figure 2 Effect of C6-ceramide on GLUT4 mRNA expression
Fully diﬀerentiated 3T3-L1 cells were treated with 5 nM TNF and 1–3 µM C6-ceramide for 12 h.
Total cellular RNA was isolated and 20 µg/lane was subjected to electrophoresis and Northern
blot analysis. (A) Graphical representation of three independent experiments. In each case the
levels of GLUT4 mRNA were normalized to β-actin or the 18 S ribosomal RNA band. Data are
plotted as the mean percentages of mRNA remaining￿S.D. (n￿ 3). (B) Representative
Northern blot analysis. Lanes 1 and 3 are controls (no treatment), lanes 2 and 4 are TNF-treated,
and lanes 5 and 6 are 1 and 3 µM C6-ceramide-treated respectively. Lanes are numbered left
to right.
treatment, GLUT4 mRNA content decreased by 60%, an eﬀect
similar in magnitude to that seen with TNF treatment (￿ 75%
decrease in GLUT4 mRNA) (Figure 2), suggesting ceramide
may be a possible mediator of the eﬀects of TNF on GLUT4
gene expression. Finally we note that addition of phosphocholine
Figure 3 Regulation of GLUT4 gene transcription by ceramide
Nuclei were isolated from 3T3-L1 adipocytes, both control (CTL) and 3 µM C6-ceramide treated
(12 h) cells, and subjected to run-on transcription analysis as we have previously described
[31]. The results demonstrate the hybridization of in vitro transcribed RNA to the indicated
cDNAs (2 µg each) or 3T3-L1 genomic DNA (0.1 µg), which were immobilized on nylon
membranes. Vector DNA (pGEM plasmid, Promega ; 2 µg/lane) was present as a control.
Following autoradiography, results were quantified using Imagequant software, Molecular
Dynamics (Sunnyville, CA, U.S.A.). The results shown are representative of an experiment
performed three times with similar results.
to the cultures to a final concentration of 50 µM had no eﬀect on
GLUT4 mRNA accumulation (results not shown).
C6-ceramide decreases GLUT4 gene transcription
Since C
￿
-ceramide can mimic TNF’s eﬀects on GLUT4 mRNA,
the question became at what level mechanistically did C
￿
-
ceramide suppress GLUT4 message levels, as TNF decreases
both GLUT4 gene transcription and mRNA stability [13]. To
determine whether the ceramide-induced suppression of GLUT4
mRNA content arose at the level of mRNA synthesis, tran-
scription of the GLUT4 gene was measured in nuclei obtained
from both control and 12 h C
￿
-ceramide-treated adipocytes
(Figure 3). Nascent ￿￿P-labelled GLUT4 and GLUT1 run-on
transcripts were quantified using Imagequant software. Exposure
of the 3T3-L1 adipocytes to C
￿
-ceramide markedly suppressed
run-on transcription of the GLUT4 and GLUT1 genes, which
decreased to￿ 35% and 30% respectively of their initial rates.
The eﬀect of ceramide on the transcription of the two transporter
genes is identical to that which we have previously reported for
TNF [9,13]. Subsequent investigations revealed that, in contrast
to TNF, C
￿
-ceramide had no eﬀect on the stability of GLUT4
mRNA (results not shown). These results are consistent with a
reduction in GLUT4 gene transcription as being responsible for
the observed eﬀects of C
￿
-ceramide on GLUT4 mRNA content
shown in Figure 2.
C6-ceramide stimulates the autophosphorylation of PKCζ and
activation of NF-κB in the 3T3-L1 adipocytes
We next investigated which signalling intermediates were acti-
vated by ceramide in the adipocytes. Recently, ceramide has been
shown to bind to and regulate the kinase activity of PKCζ in
response to TNF treatment in U937 cells [40]. Activation of the
PKC is accompanied by intramolecular autophosphorylation,
which reflects the activity state of the kinase [41]. Based on these
observations the phosphorylation state of PKCζ was determined
in the adipocytes treated with either C
￿
-ceramide or TNF.
Exposure of ￿￿P-labelled cells to 3 µM C
￿
-ceramide resulted in a
rapid and transient increase in the phosphorylation of PKCζ
(Figure 4A). When the cells were exposed to 5 nM TNF, similar
results were observed; however, as shown in Figure 4(B), both
the magnitude of autophosphorylation as well as the time course
were altered. These results are consistent with the hypothesis that
PKCζ participates in TNF-induced signalling pathways after
activation by ceramide.
Previous data from our laboratory have demonstrated that 1 h
of TNF treatment results in activation ofNF-κB in the adipocytes
[42]. We therefore evaluated the ability of C
￿
-ceramide to serve
as a second messenger for TNF in the activation of NF-κB. For
these studies, 3T3-L1 adipocytes were treated with TNF for 1
and 2 h, AA for 1.5 h, or C
￿
-ceramide for 1.5 h, and then nuclear
proteins were extracted. NF-κB activation was determined by
DNA gel shift analysis as shown in Figure 5. The data clearly
demonstrate that C
￿
-ceramide, as well as AA, is capable of
activating NF-κB in the adipocytes (Figure 5), although the
response was not as robust as that seen after TNF treatment. The
gel shift assay detected a specific DNA–protein complex formed
in response to TNF, AA or C
￿
-ceramide that was competed by
a 100-fold excess of unlabelled DNA probe but not by a similar
non-specific probe (results not shown) and thus demonstrated a
specific activation of NF-κB.
These data represent the first demonstration of ceramide
activation of both PKCζ and NF-κB in terminally diﬀerentiated
3T3-L1 adipocytes. While we have not established a link between
their activation and GLUT4 gene expression they provide the
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Figure 4 SDS/PAGE analysis of PKCζ immunoprecipitations from C6-
ceramide- and TNF-treated 3T3-L1 adipocytes
3T3-L1 adipocytes were labelled for 4 h with [32P]Pi (100 µCi/ml) and incubated for the
indicated times with 3 µM C6-ceramide (A) or 5 nM TNF (B). The cells were lysed and PKCζ
was immunoprecipitated. Immunoprecipitates of 7.5￿106cells/lane were separated on
SDS/PAGE and the gel was dried down and autoradiographed for 7 days. Identical results were
observed in three separate experiments. Specificity of the immunoprecipitation was demonstrated
by competition studies using the cognate antigen (amino acids 557–592) provided by
Boehringer Mannheim (results not shown).
Figure 5 EMSA of nuclear extracts prepared from 3T3-L1 adipocytes
Fully diﬀerentiated 3T3-L1 cells were treated with 5 nM TNF for 1 and 2 h, or 100 µM AA or
3 µM C6-ceramide for 1.5 h. Nuclear extracts were then prepared as described in the
Experimental section and 10 µg of protein from each sample was incubated with a radiolabelled
double-stranded oligonucleotide containing the NF-κB response element (5￿-AATTTCCCTGG-
AAA-GTCCCAGCGGAAAGTCCCTTGT-3￿). The binding reactions were then subjected to EMSA
analysis. The gel shifts displayed are representative of an experiment performed three times with
similar results.
basis for elucidating the components of the ceramide-initiated
signal transduction pathway, as well as a testable hypothesis for
control of GLUT4 gene expression.
DISCUSSION
In the present study, we have demonstrated that TNF regulates
GLUT4 gene expression in the 3T3-L1 adipocytes through a
ceramide-dependent pathway of signal transduction. We have
found that addition of TNF to the adipocytes resulted in a rapid
decrease in SM levels and concomitant increase in ceramide
levels. However, unlike the SM cycle described by Jayadev et al.
in HL-60 cells [26] (where the PLA
￿
￿AA pathway mediates the
eﬀects of TNF on SM hydrolysis) AA does not appear to be
involved in the TNF-induced SM turnover in 3T3-L1 cells. This
is suggested by the data in Figure 1 where SM levels did not
change after treatment with AA, oleic acid or ETYA. The
inability of fatty acids to activate the adipocyte SMase suggests
that it is not a neutral SMase, as described for the HL-60 cells
[26], but an acidic SMase, which has been suggested to mediate
the eﬀects of TNF in some cell types. Ceramide, a product
formed from the breakdown of membrane SM through the
action of SMase, has been demonstrated to act as a second
messenger, mediating the eﬀects of TNF on cell growth and
diﬀerentiation [37,42–44] and, more recently, TNF-induced
apoptosis [39]. The current study identifies ceramide as a likely
mediator of the TNF-induced decrease in GLUT4 mRNA
content by demonstrating that ceramide is capable of mimicking
the eﬀects of TNF on GLUT4 gene expression. Like TNF, C
￿
-
ceramide suppressed GLUT4 mRNA accumulation; however,
ceramide acted only by decreasing the transcription rate of the
gene, without changing the GLUT4 mRNA half-life. Thus, the
eﬀect of ceramide is localized to transcription, suggesting that
another pathway controls the TNF-induced mRNA destabil-
ization. We also examined the eﬀect of ceramide on GLUT1
transcription and observed that, in a manner identical to TNF
[9,13], ceramide decreased the transcription of the GLUT1 gene.
These results are consistent with ceramide functioning as the
mediator of TNF for the regulation of both transporters.
Contrary to our previous studies [9,13], Szalkowski et al. [45]
reported the lack of an eﬀect of TNF on GLUT1 expression.
However, in that study, the concentrations of TNF and protocol
for diﬀerentiation, as well as the duration of treatment, were
markedly diﬀerent to those in our studies, suggesting that the
discrepancy results from one or more of these diﬀerences.
With respect to TNF signalling, ceramide has been shown to
activate a membrane-associated kinase which is also activated by
TNF in intact and cell-free systems and shares the substrate
specificity of MAP kinases [46,47]. A ceramide-activated protein
phosphatase has also been described in extracts of T9 glioma
cells that may be involved in transducing the eﬀects of ceramide
[21]. To date, it is not clear whether these kinases and phos-
phatases are direct or downstream targets for ceramide and what
role they may play in mediating the biological eﬀects of ceramide.
Previous data from our laboratory demonstrated that the phos-
phatase inhibitor, okadaic acid, suppressed GLUT4 gene tran-
scription in a similar manner to TNF and ceramide [13]. As the
inhibition of a phosphatase is biochemically the same as acti-
vating a kinase these data would predict that kinase activation is
a logical intermediate in the TNF￿ceramide signalling pathway.
Recent evidence has demonstrated that ceramide specifically
activates PKCζ, suggesting that it is an immediate target for this
lipid second messenger [40]. We have determined that the 3T3-L1
adipocytes predominantly express the atypical isoform, PKCζ
with minor expression of the Ca￿+-independent isoforms ε and θ
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[42]. Based on these observations we predicted that ceramide
treatment of the cells would stimulate phosphorylation and
subsequent activation of PKCζ and indeed, immuno-
precipitations of PKCζ from [￿￿P]P
i
-labelled cells that were
incubated with C
￿
-ceramide revealed enhanced phosphorylation
of the protein within 5 min (Figure 4). Again these observations
are consistent with ceramide functioning as the second messenger
for TNF, and with the reported direct activation of PKCζ by
ceramide, the data support the placing of this PKC isoform at a
primary point in the signal transduction cascade.
The TNF induction or repression of specific genes is carried
out by nuclear transcription factors that are at the receiving end
of the signalling cascade. TNF is one of the few cytokines known
to initiate the translocation of NF-κB from the cytosol (inactive
form) to the nucleus (active form), resulting in the regulation of
TNF-responsive genes. Thus, NF-κB can be viewed as a ‘ third
messenger ’ in the signal transduction pathway mediating the
expression of TNF-responsive genes. The study presented here
demonstrates that the SMase–ceramide pathway plays a potential
role in the activation ofNF-κB by TNF in the 3T3-L1 adipocytes.
Like TNF, addition of ceramide to cells was shown to induce the
translocation of NF-κB from the cytoplasm to the nucleus,
identifying a potential mediator for TNF activation of NF-κB in
the adipocytes. The results of numerous other studies have
indicated that ceramide produced by SMase functions as a
crucial component of the TNF signalling cascade by modulating
the levels of NF-κB [18,24,48,49]. These data are not only
diagnostic for the TNF signal transduction pathway in the 3T3-
L1 adipocytes, but further confirm that ceramide is a major
second messenger of TNF action in these cells. Moreover, based
on the studies of Schutze et al. [50] where TNF-induced activation
of NF-κB was shown to be mediated by an acidic SMase, these
results would suggest that in the adipocytes an acidic SMase is
responsible for the generation of ceramide in response to TNF.
It is unclear at this time whether this nuclear transcription factor
plays a role in the suppression of the GLUT4 gene. The GLUT4
promoter does contain one NF-κB-like binding site located at
bases￿110 to￿120; however, DNA gel shift analysis indicated
no change in the binding pattern of the transcription factor with
TNF or ceramide treatment (results not shown).
In summary, we have demonstrated that ceramide appears to
be the functional mediator of TNF in the suppression of GLUT4
gene transcription. In addition, we have established that in
terminally diﬀerentiated adipocytes, ceramide activates two
major signalling intermediates, PKCζ and NF-κB. While we
have not linked activation of these intermediates to control of
GLUT4 gene expression we have established the potential for
PKCζ and NF-κB to play a role in TNF-regulated events in the
fat cell.
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